A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07673120
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • ABBV-313 — DRUG
    Injection
  • Placebo — DRUG
    Injection
  • ABBV-313 — DRUG
    Infusion
  • Placebo — DRUG
    Infusion

Study Details

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.

Key Dates

Start date
Jun 22, 2026
Status verified
Jun 2026
Primary completion
Feb 29, 2028
Completion
Feb 29, 2028

Study Design

Enrollment
64 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Part 1, Group 1: ABBV-313 or Placebo
    Participants will receive a single dose of ABBV-313 or Placebo
  • Experimental: Part 1, Group 2: ABBV-313 or Placebo
    Participants will receive a single dose of ABBV-313 or Placebo
  • Experimental: Part 1, Group 3: ABBV-313 or Placebo
    Participants will receive a single dose of ABBV-313 or Placebo
  • Experimental: Part 1, Group 4: ABBV-313 or Placebo
    Participants will receive a single dose of ABBV-313 or Placebo
  • Experimental: Part 1, Group 5: ABBV-313 or Placebo
    Participants will receive a single dose of ABBV-313 or Placebo
  • Experimental: Part 1, Group 6: ABBV-313 or Placebo
    Participants will receive a single dose of ABBV-313 or Placebo
  • Experimental: Part 2, Group 7: ABBV-313 or Placebo
    Participants will receive multiple doses of ABBV-313 or Placebo
  • Experimental: Part 2, Group 8: ABBV-313 or Placebo
    Participants will receive multiple doses of ABBV-313 or Placebo

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to Approximately Day 329 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 283495GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies